A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

← catalyst calendar

NCT06833008 · readout in 775 d

Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

85estimated

Sites

Countries

France, Italy, Spain +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-03-14

actual

When the study began enrolling

Primary completion

2028-10-03

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-10-03

estimated

The whole study's end, after follow-up

First posted

2025-02-18

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-30

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Advanced Solid Tumor

Intervention

Drug: IPN01195

Primary outcomes

what the primary-completion date above is the date OF

Part A: Percentage of participants with dose limiting toxicity (DLT)

measured Part A: within 28 days of first dose.

Part A and B: Percentage of participants experiencing treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TE SAEs).

measured From the first IPN01195 administration to 30 days after last dose.

Part A and B: Percentage of participants with dose interruptions and permanent treatment discontinuations

measured From the first study drug administration to 30 days after last dose.

Part B: Objective response rate (ORR)

measured Part B: At end of study (up to approximately 3 years)

Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed